JP2016516762A5 - - Google Patents

Download PDF

Info

Publication number
JP2016516762A5
JP2016516762A5 JP2016507059A JP2016507059A JP2016516762A5 JP 2016516762 A5 JP2016516762 A5 JP 2016516762A5 JP 2016507059 A JP2016507059 A JP 2016507059A JP 2016507059 A JP2016507059 A JP 2016507059A JP 2016516762 A5 JP2016516762 A5 JP 2016516762A5
Authority
JP
Japan
Prior art keywords
formula
pharmaceutically acceptable
acceptable salt
nalidixic acid
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016507059A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516762A (ja
Filing date
Publication date
Priority claimed from GB201306411A external-priority patent/GB201306411D0/en
Priority claimed from GB201306413A external-priority patent/GB201306413D0/en
Application filed filed Critical
Priority claimed from PCT/GB2014/051109 external-priority patent/WO2014167327A1/en
Publication of JP2016516762A publication Critical patent/JP2016516762A/ja
Publication of JP2016516762A5 publication Critical patent/JP2016516762A5/ja
Pending legal-status Critical Current

Links

JP2016507059A 2013-04-09 2014-04-09 炎症性障害の治療 Pending JP2016516762A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1306413.4 2013-04-09
GB1306411.8 2013-04-09
GB201306411A GB201306411D0 (en) 2013-04-09 2013-04-09 Treatment of inflammatory conditions
GB201306413A GB201306413D0 (en) 2013-04-09 2013-04-09 The local treatment of ophthalmic diseases
PCT/GB2014/051109 WO2014167327A1 (en) 2013-04-09 2014-04-09 The treatment of inflammatory disorders

Publications (2)

Publication Number Publication Date
JP2016516762A JP2016516762A (ja) 2016-06-09
JP2016516762A5 true JP2016516762A5 (enExample) 2017-06-01

Family

ID=50489339

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016507058A Pending JP2016516761A (ja) 2013-04-09 2014-04-09 炎症性眼疾患の局所治療
JP2016507059A Pending JP2016516762A (ja) 2013-04-09 2014-04-09 炎症性障害の治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016507058A Pending JP2016516761A (ja) 2013-04-09 2014-04-09 炎症性眼疾患の局所治療

Country Status (11)

Country Link
US (2) US20160068527A1 (enExample)
EP (2) EP2983788A1 (enExample)
JP (2) JP2016516761A (enExample)
CN (2) CN105431172A (enExample)
AU (2) AU2014252808A1 (enExample)
CA (2) CA2909111A1 (enExample)
GB (2) GB2516138C (enExample)
HK (2) HK1221190A1 (enExample)
RU (2) RU2015145135A (enExample)
WO (2) WO2014167327A1 (enExample)
ZA (2) ZA201507724B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104496986A (zh) * 2014-12-12 2015-04-08 苏州亚科化学试剂股份有限公司 萘啶酸的制备方法
EP3369422A4 (en) * 2015-10-29 2018-12-05 Teika Pharmaceutical Co., Ltd. External preparation
BR112019006160A2 (pt) * 2016-09-28 2019-06-18 Medicon Pharmaceuticals Inc composições e métodos para o tratamento das condições oftálmicas
WO2020021035A1 (en) * 2018-07-26 2020-01-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of antibiotics for the treatment of immunoglobulin a nephropathy
EP3921309A1 (en) * 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Quinolin-4-one and 4(1h)-cinnolinone compounds and methods of using same
CN114375195A (zh) * 2019-09-11 2022-04-19 阿德夫拉姆生物技术股份有限公司 使用编码阿柏西普的aav2变体治疗眼新血管疾病的方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19633480A1 (de) * 1996-08-20 1998-02-26 Bayer Ag Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren
ID23053A (id) * 1997-06-04 2000-01-20 Lilly Co Eli Karboksamida yang digunakan sebagai agonis 5-ht <if>
DE19729879C2 (de) * 1997-07-11 1999-07-08 Mann Gerhard Chem Pharm Fab Lagerstabile ophthalmische Zusammensetzungen, umfassend Diclofenac und Ofloxacin
DE19826050A1 (de) * 1998-06-12 1999-12-16 Bayer Ag Verfahren zur Herstellung von Chinolon- und Naphthyridoncarbonsäuren und deren Ester
CN1090959C (zh) * 1999-06-17 2002-09-18 卢世全 一种治疗咳喘病的中、西复方成药及制备方法
US6552020B1 (en) * 1999-07-30 2003-04-22 Allergan, Inc. Compositions including antibiotics and methods for using same
JP2001342188A (ja) * 2000-03-27 2001-12-11 Takeda Chem Ind Ltd 縮合ピラゾール誘導体、その製造法および用途
JP3648132B2 (ja) * 2000-06-19 2005-05-18 大正薬品工業株式会社 キノロン系抗菌薬液体製剤及びその包装体
NZ530845A (en) * 2001-07-06 2006-03-31 Sucampo Ag Composition for topical administration
AUPS017702A0 (en) * 2002-01-25 2002-02-14 Atopic Pty Ltd Methods and compositions for the treatment of asthma and related disorders
UA86063C2 (ru) * 2004-05-03 2009-03-25 Хермес Біосайенсез, Інк. Липосомы для снабжения лекарств
MX341797B (es) * 2004-06-24 2016-09-02 Vertex Pharmaceuticals Incorporated * Moduladores de transportadores con casete de union con atp.
JP2006028031A (ja) * 2004-07-12 2006-02-02 Ltt Bio-Pharma Co Ltd 経粘膜吸収用薬物封入ナノ粒子
CN101890167B (zh) * 2004-10-01 2017-03-01 拉姆斯科股份有限公司 可方便植入的缓释药物组合物
WO2007065024A2 (en) * 2005-12-02 2007-06-07 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
US20080138350A1 (en) * 2006-10-20 2008-06-12 Bennett Michael D Process for use of fluoroquinolones to reduce or modulate inflammation due to eye disease or ophthalmic surgery
CN101129386A (zh) * 2007-07-17 2008-02-27 长治市三宝生化药业有限公司 一种含环丙沙星和地塞米松的局部悬浮滴眼剂
WO2009037855A1 (ja) * 2007-09-21 2009-03-26 Nihon Kodoiryo Kenkyukai Co., Ltd. 口腔用及び皮膚用組成物
GB0719518D0 (en) * 2007-10-05 2007-11-14 Therapeutics Ltd E Therapy
US20100311711A1 (en) * 2007-10-11 2010-12-09 The Regents Of The University Of California Inhibitors of NAAA and Methods Thereof
MX342183B (es) * 2008-09-09 2016-09-20 Allergan Inc Suspension oftalmica para uso ocular.
CA2739893C (en) * 2008-10-07 2016-10-04 Mpex Pharmaceuticals, Inc. Inhalation of levofloxacin for reducing lung inflammation
RU2012108962A (ru) * 2009-08-19 2013-09-27 Мпекс Фармасьютикалс, Инк. Применение антибиотиков в форме аэрозоля для лечения хронической обструктивной болезни легких
EP2515907A1 (en) * 2009-12-22 2012-10-31 Deutsches Krebsforschungszentrum Fluoroquinolones for the treatment and/or prophylaxis of inflammatory diseases
US20140088199A1 (en) * 2011-04-05 2014-03-27 Optosolve Llp Ophthalmic treatments

Similar Documents

Publication Publication Date Title
JP2016516762A5 (enExample)
JP2018513107A5 (enExample)
JP2016523863A5 (enExample)
JP2010132695A5 (enExample)
JP2004514739A5 (enExample)
JP2016534063A5 (enExample)
HRP20100104T1 (hr) Kombinacije koje sadrže antimuskarinska sredstva i kortikosteroide
JP2007520508A5 (enExample)
RU2015145135A (ru) Лечение воспалительных расстройств
JP2019528316A5 (enExample)
JP2017522300A5 (enExample)
EP0946175B1 (en) USE OF A COMBINATION OF H+, K+ -ATPase INHIBITORS AND GLUCOCORTICOIDS IN THE TREATMENT OF NASAL POLYPS
JP2007522141A5 (enExample)
JP2016516761A5 (enExample)
US6599927B2 (en) Use of an H+, K+-ATPase inhibitor in the treatment of Widal&#39;s Syndrome
JP2016537432A5 (enExample)
JP2019507786A5 (enExample)
JP2013536206A5 (enExample)
JP2014520874A5 (enExample)
JP2011500731A5 (enExample)
JP2013518061A5 (enExample)
CA2993621A1 (en) Compositions comprising s1p receptor modulators
JP2017511307A5 (enExample)
JP2016502992A5 (enExample)
JP2016504343A5 (enExample)